NVAX Stock Price: Novavax Inc. recedes from multi-year tops near $114.00
|- Novavax, Inc, (NASDAQ: NVAX) trades on a firm note above $107.00.
- (NASDAQ: NVAX) stays bid although below tops near $114.00.
Shares of biotech Novavax, Inc. (NASDAQ: NVAX) are adding to Monday’s gains around the $108.00 mark following the opening bell in Wall St. on Tuesday.
In the meantime, investors remain optimistic on a potential COVID-19 vaccine, underpinning further the momentum around Novavax, Inc. (NASDAQ: NVAX) as well as other biotech companies developing candidate vaccines.
So far, Novavax, Inc. (NASDAQ: NVAX) is forecasted to announce results from its Phase 1 human study of its candidate vaccine later this month, while the Phase 2 is expected to be developed in several countries.
NVAX News
At the moment, Novavax, Inc. (NASDAQ: NVAX) is advancing 6.84% at $111.45 and faces the next hurdle at $113.98 (2020 high Jul.13) followed by $169.80 (monthly high June 2016) and then $184.60 (monthly high December 2015). On the other hand, a breach of $93.51 (low Jul.10) would aim to $89.50 (high Jun.30) and finally $61.50 (monthly high May 18).
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.